Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Mullard

Showing results (91-100 of 684) with videos related to

Pageof 69
Sort By:
Nature Reviews. Drug Discovery|December 12, 2025
Betting on β-catenin inhibitors in oncologyAsher Mullard
Nature Reviews. Drug Discovery|November 5, 2025
Novartis pays US$12 billion for Avidity's lead antibody-oligonucleotide drugsAsher Mullard
Nature Reviews. Drug Discovery|November 6, 2025
Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spotAsher Mullard
Nature Reviews. Drug Discovery|May 3, 2011
Dual fronts poised to transform melanoma therapyAsher Mullard
Nature Reviews. Drug Discovery|February 2, 2012
2011 FDA drug approvalsAsher Mullard
Nature Reviews. Drug Discovery|August 2, 2011
Partnering between pharma peers on the riseAsher Mullard
Nature|May 2, 2025
Powerful protein editors offer new ways of probing living cellsAsher Mullard
Nature Reviews. Drug Discovery|January 2, 2026
2025 FDA approvalsAsher Mullard
Nature Medicine|February 6, 2010
WHO report on drug development marred by big pharma leakAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2014
Momentum builds around new antibiotic business modelsAsher Mullard
Pageof 69

Showing results (91-100 of 684) with videos related to

Sort By:
Pageof 69
Nature Reviews. Drug Discovery|December 12, 2025
Betting on β-catenin inhibitors in oncologyAsher Mullard
Nature Reviews. Drug Discovery|November 5, 2025
Novartis pays US$12 billion for Avidity's lead antibody-oligonucleotide drugsAsher Mullard
Nature Reviews. Drug Discovery|November 6, 2025
Lilly's tirzepatide and Novo Nordisk's semaglutide vie for top drug spotAsher Mullard
Nature Reviews. Drug Discovery|May 3, 2011
Dual fronts poised to transform melanoma therapyAsher Mullard
Nature Reviews. Drug Discovery|February 2, 2012
2011 FDA drug approvalsAsher Mullard
Nature Reviews. Drug Discovery|August 2, 2011
Partnering between pharma peers on the riseAsher Mullard
Nature|May 2, 2025
Powerful protein editors offer new ways of probing living cellsAsher Mullard
Nature Reviews. Drug Discovery|January 2, 2026
2025 FDA approvalsAsher Mullard
Nature Medicine|February 6, 2010
WHO report on drug development marred by big pharma leakAsher Mullard
Nature Reviews. Drug Discovery|October 2, 2014
Momentum builds around new antibiotic business modelsAsher Mullard
Pageof 69